Genome Therapeutics Posts Reduced Q3 Revenue, Strong R&D Growth, Widened Net Loss

Nov 12, 2002

This update serves to correct an error in fact. Third-quarter revenue derived from Genome Therapeutics' GenomeVision division fell by $1.3 million year over year, not $4.2 million as originally reported. GenomeWeb regrets the error.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

What You Might Learn

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

From Whales to Urchins to Algae

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In the Skin

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

This Week in PNAS

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Main menu